T0	Participants 58 84	myelodysplastic disorders.
T1	Participants 229 275	patients with myelodysplastic syndromes (MDS).
T2	Participants 276 331	Sixty-eight evaluable patients with MDS were randomized
T3	Participants 1293 1311	patients with MDS.